Resmed Inc. diskutieren
Resmed Inc.
WKN: 895878 / Symbol: RMD / Name: ResMed / Aktie / Ausrüstung & Versorgung / Large Cap /
214,90 €
-0,42 %
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at Mizuho from $250.00 to $270.00. They now have an "outperform" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at UBS Group AG from $285.00 to $325.00. They now have a "buy" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at Royal Bank Of Canada from $294.00 to $300.00. They now have an "outperform" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at Mizuho from $270.00 to $290.00. They now have an "outperform" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) was upgraded by analysts at William Blair to a "strong-buy" rating.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) was upgraded by analysts at CLSA from a "hold" rating to an "outperform" rating.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $330.00 price target on the stock.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Morgan Stanley from $298.00 to $304.00. They now have an "overweight" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for RMD provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Amazon.com Inc. diskutieren